Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  OTC Bulletin Board  >  OncoSec Medical Inc    ONCS

ONCOSEC MEDICAL INC

(ONCS)
  Report  
SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

OncoSec Medical Inc : OncoSec CEO Punit Dhillon to Present at INTERFACE 2013 Digital Health Summit

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/04/2013 | 09:04am EDT

SAN DIEGO--OncoSec is pleased to announce that CEO and co-founder, Punit Dhillon, will be speaking at this year's INTERFACE 2013 Digital Health Summit at the Vancouver Convention Centre located in Vancouver, B.C. The international, three-day conference is a gathering of the minds among some of North America's leading influencers in health IT, digital health, and the future of medicine.

"I'm delighted to be in the company of such an esteemed group of thinkers," said Dhillon. "I look forward to sharing my thoughts on the future of cancer treatment as well as hearing from the other speakers about their innovative digital health solutions."

Dhillon will deliver his talk on Thursday, October 10 at 10:45 AM PT entitled, "Inside the Battle of Making Chemo Obsolete" and will also be participating in a panel discussion on trade and investment in the healthcare industry. Other conference speakers include Terry McBride of YYoga, Geof Auchinleck of Claris Technologies, and Dr. Steven Steinhubl of Scripps Translational Science Institute. To learn more about the event or to register, please visit: www.interfacesummit.com

While in Vancouver, Dhillon will also be speaking at the launch event for TiE Young Entrepreneurs, a unique program that helps high school students learn about the challenges and rewards of becoming an entrepreneur. The program provides the students with an opportunity to be mentored by seasoned entrepreneurs, while creating a network of like-minded aspiring entrepreneurs. The TiE Young Entrepreneurs Launch Event is slated for October 12 at SFU Segal Graduate School of Business.

About INTERFACE 2013 Digital Health Summit

INTERFACE 2013 is produced by SANOTRON, Canada's first technology accelerator focused entirely on digital health solutions that can dramatically reduce costs, significantly improve user experience and quality of life, create new jobs and opportunities, and build a sustainable healthcare system in Canada and worldwide. This is SANOTRON's second annual summit.

Contacts

for OncoSec
Ashley Letts, 778 668 3867
ashley@yulupr.com

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ONCOSEC MEDICAL INC
04/02ONCOSEC MEDICAL : Presents Promising Preclinical Data with New Product Candidate..
PU
03/29ONCOSEC MEDICAL INC : Entry into a Material Definitive Agreement, Financial Stat..
AQ
03/27ONCOSEC MEDICAL : To Host Key Opinion Leader Symposium On April 5, 2019
PU
03/08ONCOSEC MEDICAL : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AN..
AQ
02/28ONCOSEC MEDICAL : Announces Poster Presentation at 2019 American Association for..
PU
02/01ONCOSEC MEDICAL INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2018ONCOSEC MEDICAL INC : Notice of Delisting or Failure to Satisfy a Continued List..
AQ
2018ONCOSEC MEDICAL : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AN..
AQ
2018ONCOSEC MEDICAL INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2018ONCOSEC MEDICAL : Doses First Patient in KEYNOTE-890 Phase 2 Clinical Trial
AQ
More news
Financials ($)
Sales 2019 -
EBIT 2019 -34,3 M
Net income 2019 -39,9 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
Capi. / Sales 2019 0
Capi. / Sales 2020 0
Capitalization 38,0 M
Chart ONCOSEC MEDICAL INC
Duration : Period :
OncoSec Medical Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 4,00 $
Spread / Average Target 583%
EPS Revisions
Managers
NameTitle
Daniel J. O'Connor President, Chief Executive Officer & Director
Avtar S. Dhillon Non-Executive Chairman
Sara M. Bonstein Chief Operating Officer & Chief Financial Officer
Christopher G. Twitty Chief Scientific Officer
James M. DeMesa Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ONCOSEC MEDICAL INC38
IQVIA HOLDINGS INC13.89%26 146
CELLTRION, INC.--.--%23 477
LONZA GROUP14.29%21 459
INCYTE CORPORATION21.06%15 924
EXACT SCIENCES CORPORATION45.50%11 546